Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma

Mucosal melanoma (MucM) is a rare cancer with a poor prognosis and low response rate to immune checkpoint inhibition (ICI) compared to cutaneous melanoma (CM). To explore the immune microenvironment and potential drivers of MucM’s relative resistance to ICI drugs, we characterized 101 MucM tumors (43 head and neck, 31 female urogenital, 13 male urogenital, 11 anorectal, and 3 other gastro-intestinal) using bulk RNA-sequencing (RNAseq). The original publication is written by JL Vos, JJH Traets, et al. and published in JCI Insight in 2024.

Type: RNASeq
Archiver: European Genome-Phenome Archive (EGA)

1 Dataset 1 Publication

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD50000000892	This is an RNA sequencing dataset of 101 mucosal melanoma tumors. The original corresponding study is titled "Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma" by J.L. Vos et al., published in JCI Insight.	Illumina HiSeq 2500	101

Publications	Citations
Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma. Vos JL, Traets JJ, Qiao X, Seignette IM, Peters D, Wouters MW, Hooijberg E, Broeks A, van der Wal JE, Karakullukcu MB, Klop WMC, Navran A, van Beurden M, Brouwer OR, Morris LG, van Poelgeest MI, Kapiteijn E, Haanen JB, Blank CU, Zuur CL. JCI Insight 9: 2024 e179982	0